Saxagliptin for type 2 diabetes
Antonio R Chacra, MDDiabetes Center, Federal University of São Paulo, BrazilAbstract: Saxagliptin (Onglyza™) is a potent, selective, once-daily dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for improving glycemic control in patients with type 2 diabetes (T2D). By bl...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2010
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/8336f5f3fdf64e0f87c8e27233e66598 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:8336f5f3fdf64e0f87c8e27233e66598 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:8336f5f3fdf64e0f87c8e27233e665982021-12-02T03:42:26ZSaxagliptin for type 2 diabetes1178-7007https://doaj.org/article/8336f5f3fdf64e0f87c8e27233e665982010-09-01T00:00:00Zhttp://www.dovepress.com/saxagliptin-for-type-2-diabetes-a5348https://doaj.org/toc/1178-7007Antonio R Chacra, MDDiabetes Center, Federal University of São Paulo, BrazilAbstract: Saxagliptin (Onglyza™) is a potent, selective, once-daily dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for improving glycemic control in patients with type 2 diabetes (T2D). By blocking DPP-4, saxagliptin increases and prolongs the effects of incretins, a group of peptide hormones released by intestinal cells after meals, which stimulate glucose-dependent insulin secretion to lower blood glucose. In controlled clinical trials, saxagliptin administered as monotherapy or in combination with metformin, glyburide, or a thiazolidinedione improved glycemic control in a clinically significant manner, reflected by significant decreases in glycated hemoglobin (monotherapy, -0.5%; add-on to metformin, thiazolidinedione, or sulfonylurea, -0.6% to 0.9%; initial combination with metformin, -2.5%), fasting plasma glucose, and postprandial glucose compared with controls. Additionally, saxagliptin improved β-cell function, reflected as increases in homeostasis model assessment (HOMA)-2β. Saxagliptin was generally well tolerated; it did not increase hypoglycemia compared with controls, and was weight neutral. A meta-analysis of Phase II and III trials showed that saxagliptin did not increase the risk of major cardiovascular events. Professional organizations have updated their guidelines for T2D to include a DPP-4 inhibitor as an early treatment option—either as initial therapy in combination with metformin, or as add-on therapy for patients whose glycemia is inadequately controlled by a single oral antidiabetic drug.Keywords: saxagliptin, dipeptidyl peptidase-4 (DPP-4) inhibitor, type 2 diabetes Antonio R ChacraMDDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2010, Iss default, Pp 325-335 (2010) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Specialties of internal medicine RC581-951 |
| spellingShingle |
Specialties of internal medicine RC581-951 Antonio R Chacra MD Saxagliptin for type 2 diabetes |
| description |
Antonio R Chacra, MDDiabetes Center, Federal University of São Paulo, BrazilAbstract: Saxagliptin (Onglyza™) is a potent, selective, once-daily dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for improving glycemic control in patients with type 2 diabetes (T2D). By blocking DPP-4, saxagliptin increases and prolongs the effects of incretins, a group of peptide hormones released by intestinal cells after meals, which stimulate glucose-dependent insulin secretion to lower blood glucose. In controlled clinical trials, saxagliptin administered as monotherapy or in combination with metformin, glyburide, or a thiazolidinedione improved glycemic control in a clinically significant manner, reflected by significant decreases in glycated hemoglobin (monotherapy, -0.5%; add-on to metformin, thiazolidinedione, or sulfonylurea, -0.6% to 0.9%; initial combination with metformin, -2.5%), fasting plasma glucose, and postprandial glucose compared with controls. Additionally, saxagliptin improved β-cell function, reflected as increases in homeostasis model assessment (HOMA)-2β. Saxagliptin was generally well tolerated; it did not increase hypoglycemia compared with controls, and was weight neutral. A meta-analysis of Phase II and III trials showed that saxagliptin did not increase the risk of major cardiovascular events. Professional organizations have updated their guidelines for T2D to include a DPP-4 inhibitor as an early treatment option—either as initial therapy in combination with metformin, or as add-on therapy for patients whose glycemia is inadequately controlled by a single oral antidiabetic drug.Keywords: saxagliptin, dipeptidyl peptidase-4 (DPP-4) inhibitor, type 2 diabetes |
| format |
article |
| author |
Antonio R Chacra MD |
| author_facet |
Antonio R Chacra MD |
| author_sort |
Antonio R Chacra |
| title |
Saxagliptin for type 2 diabetes |
| title_short |
Saxagliptin for type 2 diabetes |
| title_full |
Saxagliptin for type 2 diabetes |
| title_fullStr |
Saxagliptin for type 2 diabetes |
| title_full_unstemmed |
Saxagliptin for type 2 diabetes |
| title_sort |
saxagliptin for type 2 diabetes |
| publisher |
Dove Medical Press |
| publishDate |
2010 |
| url |
https://doaj.org/article/8336f5f3fdf64e0f87c8e27233e66598 |
| work_keys_str_mv |
AT antoniorchacra saxagliptinfortype2diabetes AT md saxagliptinfortype2diabetes |
| _version_ |
1718401676038111232 |